CRISPR Therapeutics Q1 EPS $(1.43) Misses $(1.42) Estimate, Sales $504.00K Miss $28.11M Estimate
Portfolio Pulse from Benzinga Newsdesk
CRISPR Therapeutics (NASDAQ:CRSP) reported Q1 EPS of $(1.43), missing estimates by 0.7% and marking a 113.43% decrease from last year. Sales were $504K, missing estimates by 98.21% and representing a 99.50% decrease from the previous year.
May 08, 2024 | 9:01 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
CRISPR Therapeutics reported significantly lower than expected Q1 earnings and sales, missing estimates and showing a substantial decrease from the previous year.
The miss on both earnings per share (EPS) and sales estimates, coupled with the significant year-over-year decline in performance, is likely to negatively impact investor sentiment and the stock price in the short term. The magnitude of the miss, especially in sales which were 98.21% below estimates, indicates substantial operational challenges or market conditions that were not anticipated. This could lead to a loss of investor confidence and downward pressure on the stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100